Bothersome Bones: Challenging Osteoporosis Cases
Bothersome Bones will help you apply international guidelines to the management of challenging osteoporosis cases. CSEM’s Knowledge Transfer Activities (KTA) use a case-based approach, and pre-and post-tests during live, online sessions to help you assess your clinical management of important endocrine conditions.
1. Apply clinical risk factors, as guided by international guidelines, to inform individualized decision-making when choosing anabolic therapy over anti-resorptive therapy.
2. Compare the advantages and disadvantages of anabolic agents for osteoporosis versus other available treatment options.
3. Formulate an approach to “treatment order matters”, including key considerations when switching between anabolic to anti-resorptive therapies.
Biography:
Dr. Christopher Tran is the program director for the Endocrinology and Metabolism residency training program at the University of Ottawa. He is an assistant professor at the University of Ottawa and received Educator of the Year (Preclerkship) and the 2022 Canadian Association Medical Education Certificate of Merit awards for his contributions to medical education.
Conflicts of Interest:
I do not have a relationship with a for-profit and/or not-for-profit organization to disclose.
Biography:
Dr. Xin Feng is a clinical lecturer at the University of British Columbia. He was working in Victoria, BC and is moving to New Westminster, BC. He completed his endocrine training at the University of Calgary. His clinical interest includes osteoporosis and metabolic bone disease.
Conflicts of Interest:
Membership on advisory boards or speaker's bureau - Amgen, Bayer, Eisen, Sandoz
Biography:
Dr. Sabrina Gill earned her Bachelor’s degree in Pharmaceutical Sciences followed by her Medical degree at University of British Columbia (UBC). After completing her Internal Medicine training at the University of Alberta and subspecialty training in Endocrinology and Metabolism at UBC, Dr. Gill pursued her post-doctoral research training in Reproductive Endocrinology at the Reproductive Endocrine Unit at Massachusetts General Hospital in Boston. Dr. Gill also completed her Masters degree in Public Health in Clinical Epidemiology at the Harvard School of Public Health. She is currently an Endocrinologist at St. Paul’s Hospital, the Medical Director of the Metabolic Bone Clinic,and Clinical Professor in the Faculty of Medicine at University of British Columbia.
Conflicts of Interest:
Membership on advisory boards or speakers’ bureaus – Amgen, Lilly, Merck, BMS, NovoNordisk
Biography:
Dr. Sandra Kim is an endocrinologist at Women’s College Hospital where she is the Director of the Multidisciplinary Osteoporosis Program, and Assistant Professor of Medicine at the University of Toronto. She is the past chair of the Scientific Advisory Council for Osteoporosis Canada, and current chair of the Pharmacotherapy working group for the Osteoporosis Canada Clinical Practice Guidelines update. She is involved with the Ontario Osteoporosis Strategy in providing osteoporosis care outreach to underserviced communities in Ontario through telemedicine, and member of the Canadian panel for the International Society for Clinical Densitometry.
Conflicts of Interest:
All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity - Osteoporosis Canada (not-for-profit) Volunteer work as: Past Chair, Scientific Advisory Council, and Chair of Clinical Practice Guidelines’ Pharmacotherapy Working Group
Eli Lilly
